Immunocore Holdings PLC (IMCR) FinancialsIMCRImmunocore Holdings PLC

Immunocore Holdings PLC (IMCR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product revenue, accounting for 96.6% of total sales, equivalent to $62.91M. Another important revenue stream is Genentech. Understanding this composition is critical for investors evaluating how IMCR navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Immunocore Holdings PLC maintains a gross margin of 99.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2.58%, while the net margin is -0.70%. These profitability ratios, combined with a Return on Equity (ROE) of -4.47%, provide a clear picture of how effectively IMCR converts its operational activities into shareholder value.

In the context of the broader market, IMCR competes directly with industry leaders such as TSHA and KARD. With a market capitalization of $1.89B, it holds a significant position in the sector. When comparing efficiency, IMCR's gross margin of 99.06% stands against TSHA's N/A and KARD's N/A. Such benchmarking helps identify whether Immunocore Holdings PLC is trading at a premium or discount relative to its financial performance.

Immunocore reported $223 million in net revenue for the first half of 2026, a 16% increase, and a gross margin of 99.06% in Q2 2026, indicating strong profitability despite some losses.